Overview

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the effectiveness, safety and clinical outcome of Epoetin alfa with dosing regime in accordance with Summary of Product Characteristics in the treatment of anemia in predialysis.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Epoetin Alfa